Home > Insider Trading > Filing (0001225208-12-006697)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
9892	Bard C R Inc	BCR	Surgical & Medical Instruments & Apparatus (3841)	221454160

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1204663	H John Weiland	C/O C. R. Bard, Inc. 730 Central Avenue Murray Hill NJ 07974	President And Coo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2012-03-05	8,789	$92.91	186,910	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Acquisiton	2012-03-01	12,111	$0.00	12,111	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
12,111			No	4	A	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	5,239	Indirect	401(k) Plan

Footnotes

Sales are pursuant to a previously disclosed 10b5-1 plan.
Represents the weighted average sales price for price increments ranging from $92.67 to $93.30. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4.
These restricted stock units were granted under the 2003 Long Term Incentive Plan of C. R. Bard, Inc. (as Amended and Restated) and will be settled in common stock upon the Compensation Committee's certification of performance achievement following the completion of the performance period ending on December 31, 2014. The amount of shares reported represents the payout at target performance level, however, the reporting person will earn between 0% and 200% of target based upon the Company's performance over the performance period.